sprite-preloader
Dienstag, 06.12.2016 Börsentäglich über 12.000 News von 548 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
19.10.2016 | 22:11
(2 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

DUBLIN, October 19, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026" report to their offering.

The Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026' report provides an extensive study of the emerging market of such novel drugs, devices and surgical procedures for the treatment of elevated IOP. The focus of this study is on the applications of these novel treatment options, both marketed and under development, and their likely mid to long term evolution. These treatment options claim to provide consistent benefits related to IOP lowering and are anticipated to gain widespread adoption in the foreseen future.

The report covers various aspects of this market; some of these are outlined below:

- A detailed assessment of the current market landscape of novel drugs and devices, key players involved, the status of development of various pipeline products and the target patient segments.
- Comprehensive profiles covering mechanism of action, clinical trial details and associated developments of Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors and NO donating prostaglandins in late stage of development.
- Comprehensive profiles highlighting the IOP reduction approach, key performance drivers, safety and efficacy of novel surgical procedures that have been approved or are in advanced stages of development.
- Comparative analysis of MIGS devices based on various parameters such as drainage route, length of the implant, involvement of conjunctiva, type of procedure (ab interno or ab externo), procedure duration and ability of the device to treat 360 degrees.
- An informed view on the likely future evolution of such novel drugs, sustained release drug delivery devices and surgical procedures over the next decade. This includes sales forecasts of six novel drugs, including Rhopressa, Roclatan and Vesneo. Similarly, we have presented our view on the future market size of six drug delivery devices, including Bimatoprost SR, OTX-TP and punctal plug delivery system. We have also determined the likely future revenues for MIGS and non-MIGS surgical devices (BAGS, ABS, NIGP and NPGS).

To account for the uncertainties in the market, we have provided three market forecast scenarios that represent three different tracks of the market's evolution. Given the current unmet need for safer and more effective therapeutic options and the rich pipeline of novel drugs and devices, we expect this market to witness significant growth in the coming few years.

Opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Bob Butchofsky (Founder and CEO, Mati Therapeutics), Suzana Nahum Zilberberg (CEO, Bio-Light Life Sciences), Ronen Castro (CEO, IOPtima) and Donald Schwartz (CEO and President, Eye Sonix).

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape: Novel Drugs

5. Market Landscape: Novel Devices

6. Company And Drug Profiles

7. Company And Device Profiles

8. Market Forecast

9. MIGS Devices: Comparative Spider Web Analysis

10. Conclusion

11. Interview Transcripts

12. Appendix 1: Tabulated Data

13. Appendix 2: List Of Companies And Organizations

Companies Mentioned

  • AC Immune
  • ACADIA Pharmaceuticals
  • Acorn Biomedical
  • Actavis
  • Aerie Pharmaceuticals
  • Alcon Laboratories
  • Alcon Research
  • Allegro Investment Fun
  • Allergan
  • Allysta Pharmaceuticals
  • Alta Partners
  • Altacor
  • Amakem Therapeutics
  • Amgen
  • Amorphex Therapeutics
  • Amoun Pharmaceutical
  • AqueSys
  • Ascension Health Ventures
  • Ascension Ventures
  • AYUMI Pharmaceutical
  • Bascom Palmer Eye Institute
  • Bausch & Lomb
  • Bayer
  • Beaver-Visitec International
  • Belgian Investment Federal Fund
  • BioAxone BioSciences
  • Bio-Light Life Sciences
  • BioWin
  • Caisse de depot et placement du Quebec
  • Can-Fite BioPharma
  • Capricorn Health-Tech Fund NV
  • Care Capital
  • Clarus Ventures
  • Coherent
  • Coronis Partners
  • Cristalens
  • Crown Venture Fund
  • D. Western Therapeutics Institute
  • D.O.R.C. International
  • Deerfield Management Company
  • Delphi Ventures
  • Dendreon
  • Device Technologies
  • Devon Park Bioventures
  • EDBI
  • Ellex
  • Ellex iScience
  • Envisia Therapeutics
  • Ergo-Prevent
  • EVS Glaucoma Therapeutics
  • Eye Sonix
  • Eye Tech Care
  • Financiere Spin-off Luxembourgeoise (INVESTSUD Group)
  • Fond Européen des Matériaux
  • Foresite Capital
  • Forest Laboratories
  • ForSight VISION5
  • Fuji Laboratory
  • GBS Ventures
  • GlaucoPharm
  • Glaukos
  • Glautec
  • Graybug Vision
  • Handok
  • Healionics Corporation
  • Hercules Technology Growth Capital
  • Hicks Equity Partners
  • Horizon Technology Finance Corporation
  • Hospital Clinico San Carlos
  • Hoya Group
  • Icon Bioscience
  • InMed Pharmaceuticals
  • InnFocus
  • Innovative Therapie und Diagnostik GmbH
  • Inotek Pharmaceuticals
  • InSite Vision
  • International Medical Distribution
  • InView Medical
  • IOPtima
  • Iridex Corporation
  • Isarna Therapeutics
  • iScience Interventional
  • Iskowitz Instrumental SRL
  • Ivantis
  • iSTAR Medical
  • Kadmon
  • Kala Pharmaceuticals
  • Kowa Company
  • Leo Lens Technology
  • Lexicon Pharmaceuticals
  • Makina Optik Ticaret
  • Marathon
  • Mati Therapeutics
  • McGee Eye Institute
  • MedImmune Ventures
  • Medisurg
  • Meditor Capital Management
  • MemorialCare Innovation Fund
  • Merck & Co.
  • MicroOptx Medical
  • Miller School of Medicine
  • Mitsubishi UFJ Capital
  • Namur Invest - Preface
  • NEMUS Bioscience
  • Neomedix
  • New Enterprise Associates
  • New World Medical
  • NicOx
  • Novaliq GmbH
  • Novartis
  • Ocular Therapeutix
  • Oculis Pharma
  • OftalMedica srl
  • OHR Pharmaceutical
  • Ono Pharmaceuticals
  • OphthaliX
  • Ophthalmos
  • Osage University
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Palobiofarma
  • Peregrine Ophthalmic
  • Pfizer
  • Pioneer Pharma
  • Pitango Venture Capital
  • New Enterprise Associates (NEA)
  • Polyactiva
  • pSivida
  • Radikal Therapeutics
  • Ramot at Tel Aviv University
  • Regeneron
  • Replenish
  • Rheon Medical
  • Rho Ventures
  • Roche
  • Rosellini Scientific Benelux
  • Saints Capital Everest
  • Salix
  • Sanoculis
  • Sanofi
  • Santen Pharmaceutical
  • Scientific Health Development Partners
  • Senju Pharmaceutical
  • Shire
  • Showa Yakuhin
  • Sight Sciences
  • Société Régionale d'Investissement de Wallonie (SRIW)
  • Sofinnova Ventures
  • SOLX
  • STAAR Surgical
  • Sun Pharma company
  • Sylentis
  • Technomix SA
  • Tisbury Pharmaceuticals
  • Tokyo New Drug Research Laboratories
  • TPG Biotech
  • Transcend Medical
  • Ube Industries
  • University of Miami
  • University of Oklahoma
  • University of Washington
  • Valeant Pharmaceuticals International
  • Vertex Ventures
  • Wakamoto
  • Yotsuya Shirato Eye Clinic

For more information about this report visit http://www.researchandmarkets.com/research/ls4299/novel_drugs_and

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


© 2016 PR Newswire